Cefepime

Chapman, Therese M; Perry, Caroline M.

doi:10.1007/bf03256641

Cited by 61 publications

(9 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, renal insufficiency often occurs as a consequence of the critical illness with organ failure. Thus, to ensure therapeutic levels and avoid neurological toxicity, TDM of cefepime should be used to optimize cefepime therapy in these patients .…”

Section: Introductionmentioning

confidence: 99%

An MEKC assay for the therapeutic drug monitoring of cefepime

Theurillat

Sendi

Thormann

2013

J of Separation Science

View full text Add to dashboard Cite

The development of a robust assay based on MEKC for cefepime in human serum and plasma with internal quality assurance is reported. Sample preparation comprises protein precipitation in the presence of SDS at pH 4.5. This is a gentle approach for which decomposition of cefepime during sample handling is negligible. After hydrodynamic sample injection of the supernatant, analysis occurs in a phosphate/borate buffer at pH 9.1 with 75 mM SDS using normal polarity and analyte detection at 257 nm. The MEKC run time interval and throughput are about 5 min and seven samples per hour, respectively. The calibration range for cefepime is 1-60 μg/mL, with 1 μg/mL being the LOQ. The performance of the assay with multilevel internal calibration was assessed with calibration and control samples. The assay is shown to be simple, inexpensive, reproducible, and robust. It was applied to determine cefepime levels in the sera of critically ill patients and to assess the instability of cefepime in patient and control samples. Our data revealed that serum containing cefepime can be stored at -20°C for a short time, whereas for long-term storage, samples have to be kept at -70°C.

show abstract

Section: Introductionmentioning

confidence: 99%

An MEKC assay for the therapeutic drug monitoring of cefepime

Theurillat

Sendi

Thormann

2013

J of Separation Science

View full text Add to dashboard Cite

show abstract

“…The rate of mortality of patients infected nosocomially with P. aeruginosa is very high, with rates reported to be from ϳ30 to 50% (8)(9)(10). The emergence of clinical isolates of P. aeruginosa that exhibit resistance to one or more antibiotics, including fluoroquinolones, carbapenems, and a fourth-generation cephalosporin (cefepime) that is currently the antibiotic of choice for pseudomonal infections (11), severely limits treatment options (12)(13)(14)(15)(16)(17). Consequently, there is an urgent need for new therapeutic agents with activity against this pathogen (18).…”

mentioning

confidence: 99%

Penicillin-Binding Protein 3 Is Essential for Growth of Pseudomonas aeruginosa

Chen

Zhang

Davies

2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Penicillin-binding proteins (PBPs) function as transpeptidases, carboxypeptidases, or endopeptidases during peptidoglycan synthesis in bacteria. As the well-known drug targets for ␤-lactam antibiotics, the physiological functions of PBPs and whether they are essential for growth are of significant interest. The pathogen Pseudomonas aeruginosa poses a particular risk to immunocompromised and cystic fibrosis patients, and infections caused by this pathogen are difficult to treat due to antibiotic resistance. To identify potential drug targets among the PBPs in P. aeruginosa, we performed gene knockouts of all the high-molecular-mass (HMM) PBPs and determined the impacts on cell growth and morphology, susceptibility to ␤-lactams, peptidoglycan structure, virulence, and pathogenicity. Disruptions of the transpeptidase domains of most HMM PBPs, including double disruptions, had only minimal effects on cell growth. The exception was PBP3, where cell growth occurred only when the protein was conditionally expressed on an integrated plasmid. Conditional deletion of PBP3 also caused a defect in cell division and increased susceptibility to ␤-lactams. Knockout of PBP1a led to impaired motility, and this observation, together with its localization at the cell poles, suggests its involvement in flagellar function. Overall, these findings reveal that PBP3 represents the most promising target for drug discovery against P. aeruginosa, whereas other HMM PBPs have less potential.

show abstract

Section: Discussionmentioning

confidence: 92%

“…The clinical efficacy of cefepime was previously confirmed by comparative and non-comparative studies conducted many years ago [ 23 , 24 ]. Cefepime was considered useful in the management of pneumonia, and it is also active against organisms that show resistance to other drugs [ 23 , 24 ]. Fosfomycin is widely used for nosocomial-acquired infections in hospitals because of its good efficacy against Gram-negative bacteria [ 25 , 26 ].…”

Section: Discussionmentioning

confidence: 92%

Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis – an observational study

Yayan

Ghebremedhin

Rasche

2016

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

BackgroundMany antibiotics have no effect on Gram-positive and Gram-negative microbes, which necessitates the prescription of broad-spectrum antimicrobial agents that can lead to increased risk of antibiotic resistance. These pathogens constitute a further threat because they are also resistant to numerous beta-lactam antibiotics, as well as other antibiotic groups. This study retrospectively investigates antimicrobial resistance in hospitalized patients suffering from pneumonia triggered by Gram-negative Serratia marcescens or Proteus mirabilis.MethodsThe demographic and clinical data analyzed in this study were obtained from the clinical databank of the HELIOS Clinic, Witten/Herdecke University, Wuppertal, Germany, for inpatients presenting with pneumonia triggered by S. marcescens or P. mirabilis from 2004 to 2014. An antibiogram was conducted for the antibiotics utilized as part of the management of patients with pneumonia triggered by these two pathogens.ResultsPneumonia was caused by Gram-negative bacteria in 115 patients during the study period from January 1, 2004, to August 12, 2014. Of these, 43 (37.4 %) hospitalized patients [26 males (60.5 %, 95 % CI 45.9 %–75.1 %) and 17 females (39.5 %, 95 % CI 24.9 %–54.1 %)] with mean age of 66.2 ± 13.4 years had pneumonia triggered by S. marcescens, while 20 (17.4 %) patients [14 males (70 %, 95 % CI 49.9 %–90.1 %) and 6 females (30 %, 95 % CI 9.9 %–50.1 %)] with a mean age of 64.6 ± 12.8 years had pneumonia caused by P. mirabilis. S. marcescens showed an increased antibiotic resistance to ampicillin (100 %), ampicillin-sulbactam (100 %), and cefuroxime (100 %). P. mirabilis had a high resistance to tetracycline (100 %) and ampicillin (55 %). S. marcescens (P < 0.0001) and P. mirabilis (P = 0.0003) demonstrated no resistance to cefepime in these patients with pneumonia.ConclusionsS. marcescens and P. mirabilis were resistant to several commonly used antimicrobial agents, but showed no resistance to cefepime.

show abstract

Cefepime

Cited by 61 publications

References 116 publications

An MEKC assay for the therapeutic drug monitoring of cefepime

An MEKC assay for the therapeutic drug monitoring of cefepime

Penicillin-Binding Protein 3 Is Essential for Growth of Pseudomonas aeruginosa

Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis – an observational study

Contact Info

Product

Resources

About